Does the Senate vote on stem-cell research matter?
By Richard Hayes,
San Francisco Chronicle
| 07. 19. 2006
YES: It's a step toward needed oversight and regulation
After years of rancorous debate, Tuesday's vote by the U.S. Senate on a package of stem-cell research bills suggests that responsible bipartisan action actually may be possible.
Nineteen Republican senators broke with the anti-abortion base of their party and with President Bush, by voting to lift the restrictions imposed five years ago by the president on federal funding for stem-cell research.
On the other side of the aisle, pro-choice Democrats voted to support a companion bill banning the intentional creation and abortion of fetuses in order to use their tissues for experimental purposes. Although no one, as far as anyone knows, has proposed doing this at this time, the vote affirms that liberals and conservatives can agree that some forms of biomedical research are ethically unacceptable and should be prohibited.
Also encouraging was what was left out of the package, notably, any move to authorize federal funding for research cloning, a procedure fraught with risks. At one time, cloning was thought to be necessary for stem-cell therapy to work, but many scientists increasingly believe that this is not the case...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...